

AspirinWorks[®] Reference Synopsis

Patient population: key words	Publication	Synopsis
>Secondary prevention >Risk factor >Statins	Circulation. 2008; 118:000-000. J. Eikelboom, et.al. Association between incomplete suppression of thromboxane generation with usual doses of ASA and increased risk of subsequent serious vascular events	11-dehydro thromboxane B ₂ (11dhTxB ₂) is an independent, modifiable predictor of risk for stroke, MI and cardiovascular death. Statins and aspirin lower the concentrations of 11dhTxB ₂ . Randomization to clopidogrel did not reduce 11dhTxB ₂ levels Randomization to clopidogrel vs. placebo did not reduce the hazard of cardiovascular events in patients in the highest quartile of 11dhTxB ₂ levels.
>Asymptomatic for coronary artery disease. >Primary prevention >Risk score	J Cardiol 2006; 98:774-779. Faraday N., et.al. Relation Between Atherosclerosis Risk Factors and Aspirin Resistance in Primary Prevention Population	"Higher (urinary 11-dehydro thromboxane B ₂), which reflects decreased suppression of thromboxane production in vivo, is ... associated with atherosclerosis risk factors, suggesting that this measurement may represent the most relevant approach for identifying asymptomatic subjects whose aspirin treatment will "fail."
>Secondary Prevention	Circulation.2002; 105: 1650-1655. Eikelboom JW et. al. Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events.	Outcome data from patients enrolled in the Heart Outcomes Prevention Evaluation (HOPE) Study, recently published in Circulation, showed that patients who did not respond well to aspirin, as determined by 11-dehydrothromboxane B ₂ levels, have an increased risk of myocardial infarction and cardiovascular death.
>Secondary Prevention Review	Arch Intern Med 2007; 167:1593-9. Snoep JD, et al. Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events	"patients biochemically identified as having laboratory aspirin resistance are more likely to also have "clinical resistance" to aspirin because they exhibit significantly higher risks of recurrent cardiovascular events compared with patients who are identified as (laboratory) aspirin sensitive."

AspirinWorks® Reference Synopsis

Patient population: key words	Publication	Synopsis
>Secondary Prevention >Inflammation >Dyslipidemia	Basic & Clinical Pharmacology & Toxicology 2006;98:503-509. Markuszewski L. et. al. <i>Reduced Blood Platelet Sensitivity to Aspirin in Coronary Artery Disease: Are Dyslipidemia and Inflammatory States Possible Factors Predisposing to Sub-Optimal Platelet Response to Aspirin?</i>	“platelet responsiveness to acetylsalicylic acid was reduced in a group of coronary artery disease patients compared to controls without coronary disease.”
>Stroke >Acquired Resistance	Stroke 1994.25; 12:2331-2336. Helgason CM, et. al. <i>Development of Aspirin Resistance IN persons With Previous Ischemic Stroke.</i>	“The antiplatelet (and presumably the antithrombotic) effect of a fixed dose of ASA is not constant over time in all individuals.”
>Healthy Subjects	Stroke. 2005; 36:276-280. Gonzalez-Conejero R., et.al. <i>Biological Assessment of Aspirin Efficacy on Healthy Individuals</i>	“Full resistance of healthy subjects to aspirin is rather unlikely.”
>Aspirin bypass mechanism	Thrombosis Research (2007) Tran HA, et. al. <i>Aspirin Resistance</i>	“The observation of an independent and graded association between urinary thromboxane and cardiovascular risk throughout the range of urinary thromboxane concentrations provides evidence that aspirin bypass is a more common problem than originally believed.”
>Anti-platelet drugs	Arteriosclerosis, Thrombosis, and Vascular Biology. 2004; 24:1980. Cattaneo M. <i>Aspirin and Clopidogrel – efficacy, safety and the issue of drug resistance.</i>	“Lacking a reproducible and highly sensitive and specific method to study TxA ₂ -dependent platelet function, the pharmacological response to aspirin treatment should be assessed by measuring the degree of inhibition of TxA ₂ production. This could be performed by measuring either serum TxB ₂ or the urinary excretion of TxB ₂ metabolites. Therefore, based on the available techniques, the only acceptable definition of aspirin resistance should rely on the demonstration of an insufficient inhibition of TxA ₂ production.”

AspirinWorks[®] Reference Synopsis

Patient population: key words	Publication	Synopsis
>Review	J Thromb Haemost. 2005; 3: 1655-1662. Szczklik A., et al. <i>Aspirin resistance.</i>	<p>“In summary, laboratory tests of platelet function, while able in general to show inhibitory effect of aspirin, are not specific and sensitive enough to quantitatively reflect platelet responsiveness to the drug. Percentages of subjects identified as aspirin-resistant vary widely depending on the method used. Their reproducibility, i.e. confirmation of ‘resistance’ in time is lacking.”</p> <p>“More specific in this respect are measurements of whole-blood TXB₂ production and of urinary excretion of its metabolite, 11-dehydro-thromboxane B₂.”</p>
>Review	Journal of Thrombosis and Haemostasis 2003; 1: 1710-1713. <i>Aspirin Resistance: definition, mechanisms and clinical read-outs.</i>	“Thus, there may be clinical circumstances under which the mechanism(s) and cellular source(s) of TxA ₂ biosynthesis are inadequately blocked by conventional antiplatelet doses of aspirin.”
>Review	Formulary. 2006; 41: 192-201. Chow SL, et. al. <i>Aspirin resistance: a growing concern.</i>	“Therapeutic failure due to aspirin resistance can have a major impact on the cost of treating patients with coronary heart disease and stroke.”
>Review	Ann Intern Med. 2005; 142: 370-380. Sanderson S. et. al. <i>Narrative Review: Aspirin Resistance and Its Critical Implications</i>	“Aspirin is currently the most cost-effective drug for the secondary prevention of cardiovascular disease, but treatment failures are relatively common.”